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Abstract
Rationale Working memory dysfunction is frequently
observed in schizophrenia. The neural mechanisms under-
lying this dysfunction remain unclear, with functional
neuroimaging studies reporting increased, decreased or
unchanged activation compared to controls.
Objectives We investigated the neural correlates of spatial
working memory in schizophrenia with particular consid-
eration of effects of antipsychotic treatment and relation to
performance levels in the patient group.
Method We used functional magnetic resonance imaging
and studied the blood-oxygen-level-dependent (BOLD)
response of 45 schizophrenia outpatients and 19 healthy
controls during a parametric spatial n-back task.
Results Performance in both groups deteriorated with in-
creasing memory load (0-back, 1-back, 2-back), but the two
groups did not significantly differ in performance overall or as
a function of load. Patients produced stronger BOLD signal in
occipital and lateral prefrontal cortex during task performance
than controls. This difference increased with increasing
working memory load in the prefrontal areas. We also found
that in patients with good task performance, the BOLD
response in left prefrontal cortex showed a stronger parametric
increase with working memory load than in patients with poor
performance. Second-generation antipsychotics were inde-
pendently associated with left prefrontal BOLD increase in
response to working memory load, whereas first-generation
antipsychotics were associated with BOLD decrease with
increasing load in this area.
Conclusions Together, these findings suggest that in
schizophrenia patients, normal working memory task
performance may be achieved through compensatory neural
activity, especially in well-performing patients and in those
treated with second-generation antipsychotics.
Keywords Schizophrenia . Spatial working memory .
Functional brain imaging . Antipsychotics . Biomarker
Introduction
Working memory is defined as the capacity to mentally
maintain and manipulate information over short time
periods. As such, it is an important cognitive function
underlying a range of behaviours and everyday tasks.
Working memory deficits are frequently observed in
schizophrenia (Barch 2005; Goldman-Rakic 1994; Park
and Holzman 1992). The deficit has been observed at
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different illness stages and may be a predictor of clinical
and functional outcome as well as a relevant target for
treatments aimed at cognitive enhancement (Green and
Nuechterlein 2004; Greenwood et al. 2005; Liddle 2000).
Basic neuroscience studies have shown that the dorso-
lateral prefrontal cortex (DLPFC) as well as parietal cortex
and subcortical projection targets are of critical importance
in working memory (Barch 2005; Gruber and von Cramon
2003). However, despite the often replicated observation of
working memory impairments in schizophrenia, brain activa-
tion studies using functional magnetic resonance imaging
(fMRI) have not yet reliably identified the neural circuits
underlying this impairment. While initial studies observed
reduced activation in frontal areas in patients (termed
hypofrontality), other studies have reported increased activa-
tion or no significant differences between patients and controls
(for review, see (Glahn et al. 2005; Linden 2009; Manoach
2003). A variety of factors such as task design and patient
characteristics are likely to play a role, but task difficulty,
subject performance levels, and pharmacological treatment
status are considered to be particularly important factors.
Regarding the related factors of task difficulty and
performance, it has been argued (Manoach 2003) and
demonstrated empirically (Callicott et al. 2003; Potkin et
al. 2009) that activation levels may fall along an inverted U
shape distribution reflecting task difficulty. This curve may
differ between patients and healthy controls, with patients
showing hyperactivations relative to controls at easier task
difficulty levels (or when no behavioural impairments are
seen) and hypoactivations at greater task difficulty (or when
behavioural impairments are seen).
Regarding pharmacological treatment, the effects of anti-
psychotic medication have been addressed in a number of
studies. These compounds have been shown to influence the
blood-oxygen-level-dependent (BOLD) signal during perfor-
mance of a variety of cognitive and behavioural paradigms.
Specifically, a number of studies have shown normalisation of
hypofunction in schizophrenia with second-generation (SGA)
but not first-generation antipsychotics (FGA) across a range of
neurocognitive paradigms (Braus et al. 1999; Honey et al.
1999; Jones et al. 2004; Kumari et al. 2007; Meisenzahl et al.
2006; Stephan et al. 2001; for review see Davis et al. 2005;
Kumari and Cooke 2006). However, not all studies have
observed this effect (Surguladze et al. 2007), and other work
points to task dependence of treatment effects. For example,
Schlagenhauf et al. (2008) found that switching from FGA to
olanzapine led to increased BOLD in the left DLPFC during
a 0-back attentional condition but not during a 2-back
working memory condition, relative to baseline.
The aims of this study were to further explore the
macroscopic neural circuits underlying working memory task
performance in a large sample of schizophrenia patients. More
work is needed in this area due to the inconsistencies in the
literature and in order to build up the evidence base especially
in relation to the not yet clarified issue of hypo- vs. hyper-
frontality (Karch et al. 2009; Manoach 2003; Potkin et al.
2009; Schneider et al. 2007; Tan et al. 2005). Additionally,
we aimed to examine differences in BOLD signal between
patients treated with FGA compared to SGA. This aim is of
relevance considering that working memory as well as the
underlying BOLD response may represent promising treat-
ment targets or biomarkers in drug development (Green and
Nuechterlein 2004; Migo et al. 2011). To study working
memory, we used a spatial, parametric n-back task. The
n-back task is a widely used paradigm that may represent
an intermediate phenotype reflecting genetic vulnerability
to schizophrenia as well as a potential treatment target
(Barch and Smith 2008; Egan et al. 2001; Linden 2009).
The parametric design of the task allowed us to test for
effects of working memory load on BOLD signal as well
as its modulation by antipsychotic treatment.
Method
Participants
Patients with a DSM-IV diagnosis of schizophrenia
(American Psychiatric Association 1994) were recruited
from the South London and Maudsley catchment area.
Patients were (ii) if treated, on stable doses of antipsy-
chotics for ≥2 years and on their present antipsychotic
for >3 months, (iii) in a stable phase of the illness with
stable symptoms for at least 3 months, (iv) living in the
community or long stay/rehabilitation wards, and (v) free
of any co-morbid psychiatric diagnosis. Symptom severity
was rated using the Positive and Negative Syndrome Scale
(PANSS; Kay et al. 1987).
Healthy controls were recruited via local advertisements
from the same geographical area as the patients. Controls were
required to be free from past or current drug abuse and were
screened by an experienced psychiatrist to exclude current
psychiatric conditions using the Structured Clinical Interview
for DSM Axis I Disorders (First et al. 1996).
For both groups, only right-handed participants were
included. An additional inclusion criterion for all partic-
ipants was the absence of a history of neurological
conditions or head injury. Participants provided written
informed consent, and the study had research ethics
committee permission.
fMRI task
The task (see Kumari et al. 2009) was a parametric spatial
n-back paradigm that involved monitoring locations of dots
within a diamond-shaped box on the screen at a given delay
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from the original occurrence (0-back, 1-back, or 2-back).
Participants viewed the paradigm projected onto a screen
through a prismatic mirror. They were required to press the
button on every trial, using the right thumb, corresponding
to the correct location of the 0-back, 1-back, or 2-back
stimulus (location of dots random). The level of chance
performance was 25%.
Each condition (0-back, 1-back, 2-back) was presented
five times in 30-s blocks in pseudo-random order, control-
ling for order effects. Each block contained 15 stimulus
presentations (stimulus duration = 450 ms, interstimulus-
interval = 1,500 ms) and began with a 750-ms text delay
allowing the participants to notice a change in task demand/
condition. There were 15-s rest blocks (presentation of the
word “Rest” on the screen) between active blocks and
following the last active block (thus, there was a total of 15
rest blocks). The experiment lasted 11.25 min. Participants
were requested to abstain from alcohol for at least 24 h
before testing and underwent task familiarisation before
scanning.
fMRI data acquisition
Echoplanar MR images of the whole brain were acquired
using a Signa scanner (General Electric, Milwaukee,
Wisconsin) at 1.5-Tesla field strength. In each of 16 near-
axial noncontiguous planes parallel to the intercommissural
plane, 225 T2*-weighted MR images depicting BOLD
contrast were acquired over the experiment with echo time
(TE) = 40 ms, repetition time (TR) = 3,000 ms, field of view
(FOV) = 240 mm, in-plane resolution = 3.75×3.75 mm, slice
thickness = 7.0 mm, and interslice gap = 0.7 mm.
N-back performance data analysis
The key-dependent variable measuring the success of n-back
task performance was the percentage of correct responses.
Additionally, we investigated the percentage of omission
errors (failures to respond) and the latency of correct
responses (in milliseconds). Data were analysed in SPSS
Release 15.0.0 using repeated measures analysis of variance
(ANOVA) with group (patients, controls) as between-
subjects factor and load (0-back, 1-back, 2-back) as within-
subjects factor to assess main and interaction effects. Eta
squared (ηp
2) is given as a measure of effect size.
fMRI data analysis
fMRI data analysis was carried out using Statistical
Parametric Mapping software (SPM5; http://www.fil.ion.
ucl.ac.uk/spm) running in Matlab R2008a (The MathWorks
Inc.). Images were first motion corrected, spatially trans-
formed (MNI template), smoothed (8 mm full-width-at-
half-maximum Gaussian filter). A high-pass filter with a
cut-off of 128 s was applied.
Data were analysed within the framework of the general
linear model implemented in SPM5. At the single-subject
level contrast maps of each of the three conditions (0-back,
1-back, 2-back) were created with rest as implicit baseline
by modelling, at each voxel, each condition using a boxcar
function which incorporates the delay inherent in the
hemodynamic response. Motion parameters obtained from
the realignment pre-processing step were included as
covariates at this stage. The resulting maps were entered
into a random-effects procedure at the second level to
investigate the main effect of group (patients, controls), the
main effect of load (0-back, 1-back, 2-back), and the group-
by-load interaction. The threshold of significance for these
analyses was set at p = 0.05 (corrected cluster level) with a
height threshold of p < 0.001 at the voxel level.
The group-by-load interaction effect was considered the
first key result in this study; viz. differences between patients
and controls in the brain functional response to parametric
working memory increase. Therefore, while subsequent
analyses of performance and treatment effects within the
patient group were carried out first using an anatomically
unconstrained whole-brain voxelwise method in SPM5, any
such analyses were also repeated using a regions of interest
(ROI) approach. ROIs were created by extracting the signal
(using the MarsBaR toolbox implemented in SPM5; Brett et
al. 2002) from clusters that showed a significant group-by-
load interaction. Statistical analyses of these ROIs in relation
to performance and treatment were carried out using
ANOVA in SPSS 15.0.0 as described below; these analyses
thus allowed addressing the question of how areas in which
patients differ from controls as a function of processing
demands are associated with task performance and antipsy-
chotic treatment within the patient group.
In order to investigate the role of performance levels on
BOLD signal within the patient group, a performance (high,
low) variable was created by splitting the patient group into
those with high and those with low overall percentage of
correct responses along the median of the patient group (the
subject with the median score was excluded). These two
patient groups were first compared to each other in clinical,
demographic, and performance data. The two groups were
then compared to each other in BOLD data, first across the
entire brain in SPM5 and then restricted to ROIs using
ANOVA in SPSS with performance (high, low) as between-
subjects factor and load (0-back, 1-back, 2-back) as within-
subjects factor. The effect size measure Eta squared (ηp
2) is
given for these effects.
In order to assess effects of antipsychotic treatment on
task performance and BOLD response, the patient sample
was split into those treated with FGA (N = 6) and those
treated with SGA (N = 38) antipsychotics (one patient was
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unmedicated at the time of fMRI scanning and was
excluded for the purpose of this analysis). These two
groups were then compared to each other in clinical,
demographic, and performance data. The two groups were
also compared to each other in BOLD data, first across the
entire brain in SPM5 and then restricted to ROIs using
ANOVA in SPSS with treatment (FGA, SGA) as between-
subjects factor and load (0-back, 1-back, 2-back) as within-
subjects factor. Eta squared (ηp
2) is again given.
Finally, the relationship between BOLD and symptom
severity (PANSS) was investigated in the patient sample
(first across all voxels in the whole brain in SPM5 and
subsequently in the extracted ROIs in SPSS).
MNI coordinates of peaks within significant clusters were
transformed to Talairach coordinates using a non-linear
algorithm (see http://imaging.mrc-cbu.cam.ac.uk/imaging/
MniTalairach). The atlas of Talairach and Tournoux (1988)




A total of 64 participants completed the study, consisting of
45 patients with schizophrenia and 19 controls. Demo-
graphic and clinical data are summarised in Table 1. The
patient and control groups did not differ significantly on
demographic variables with the exception of years spent in
full-time education, which may be expected given that
schizophrenia is commonly associated with lower than
expected educational achievement (Green 2001; see also
Surguladze et al. 2007).
The majority of patients (N = 38) were treated with SGA
(clozapine = 10, risperidone = 7, olanzapine = 16,
amisulpride = 2, aripiprazole = 3), six patients were treated
with FGA (haloperidol = 1, flupentixol = 2, sulpiride = 2,
chlorpromazine = 1), and one patient was untreated at time
of fMRI testing.
A number of patients were co-medicated with anticholin-
ergic, benzodiazepine, mood stabilising, or antidepressant
compounds. Anticholinergic compounds were administered
to three patients on FGA and to two patients on SGA.
Benzodiazepines were administered to four patients on SGA.
Mood stabilisers were administered to one patient on FGA
and eight patients on SGA. Antidepressants were adminis-
tered to two patients on FGA and 15 patients on SGA.
Working memory task performance
Working memory task performance data are shown in
Table 2. The patient and control groups did not significantly
differ in percent correct trials (F[1,62] = 2.17, p=0.15, ηp
2 =
0.03). There was an effect of load on percent correct trials (F
[2,124] = 73.47, p < 0.001, ηp
2 = 0.54), indicating fewer
correct responses with increasing load, but no group-by-load
interaction (F[2,124] = 1.27, p = 0.29, ηp
2 = 0.02).
The groups also did not significantly differ in the latency to
correct trials (F[1,61] = 1.00, p = 0.32, ηp
2 = 0.02). As with
percent correct responses, there was an effect of load on
latency (F[2,122] = 17.11, p < 0.001, ηp
2 = 0.22), indicating
longer latencies with increasing load, but no group-by-load
interaction (F[2,122] = 0.80, p = 0.45, ηp
2 = 0.01).
Table 1 Demographic and clinical data
Patients (N=45) Controls (N=19) Group comparison
Age (years) 37.33 (8.19) 33.32 (9.21) t=−1.73, df=62, p=0.09
Gender (N male/N female) 35/10 12/7 χ2=1.46, df=1, p=0.23
Ethnicity (N Caucasian/N other) 19/26 12/7 χ2=2.34, df=1, p=0.13
Years of education 13.36 (2.33) 14.95 (2.92) t=2.32, df=62, p=0.02
Parental SES 2.58 (1.08) 2.26 (1.20) Z= −1.06, p=0.29
Duration of illness (years) 13.49 (9.78) – –
Age of onset (years) 23.84 (6.58) – –
Antipsychotic treatment (N SGA/N FGA) 38/6a – –
PANSS positive symptoms 16.18 (4.72) – –
PANSS negative symptoms 17.67 (4.48) – –
PANSS general psychopathology 32.49 (6.01) – –
PANSS total score 66.33 (12.66) – –
Data represent means (and standard deviations) unless indicated otherwise. Socio-economic status (SES) is measured in professional achievement
from 1 (professional) to 4 (manual). All participants were right-handed
PANSS positive and negative syndrome scale, SGA second-generation antipsychotics, FGA first-generation antipsychotics
a One patient was untreated at the time of fMRI scanning
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Similarly, there was an effect of load on the percentage
of omission errors (F[2,124] = 38.24, p<0.001, ηp
2 =0.38),
indicating more omission errors with increasing load, but
no effect of group (F[1,62] = 0.04, p = 0.85, ηp
2 = 0.001)
or group-by-load interaction (F[2,124] = 0.23, p = 0.80,
ηp
2 = 0.004).
BOLD response by group and load
Both groups activated an extensive fronto-parieto-striato-
thalamo-cerebellar network during performance of the n-
back task. Figure 1 shows the activation of the combined
group as a function of load (i.e., increase in BOLD signal
with increasing working memory load); the main effect of
task (across conditions of load) in the combined sample
gave a very similar result.
The main effect of group (across conditions of load)
revealed three clusters of increased activation (p < 0.05
corrected cluster level) in patients relative to controls: (1)
occipital cortex (BA17; Talairach coordinates of peak
voxel, x = −20, y = −88, z = −9; 857 voxels; Z = 4.39)
extending into the cerebellum; (2) left middle frontal gyrus
(BA9; x = −46, y = 15, z = 36; 1,913 voxels; Z = 4.26)
extending into pre- and postcentral gyrus; and (3) right
inferior frontal gyrus (BA45/47; x = 46, y = 18, z = 18; 854
voxels; Z = 4.06) extending into right middle frontal
gyrus. In contrast, there were no significant increases in
controls relative to patients at the corrected or uncorrect-
ed cluster level and there were no significant voxels at
the chosen height threshold (p < 0.001).
The group-by-load interaction (Fig. 2) revealed two
significant clusters (p < 0.05 corrected cluster level): (1) left
middle frontal gyrus (BA9; x = −46, y = 17, z = 36; 2,032
voxels; Z = 4.43) and (2) right inferior frontal gyrus (BA45/
47; x = 46, y = 18, z = 18; 749 voxels; Z = 3.94) extending
into right middle frontal gyrus. A third cluster with a peak in
the occipital cortex (BA17; x = −22, y = −86, z = −11; 535
voxels; Z = 4.10) showed the same pattern but narrowly
missed the level of statistical significance (p = 0.054,
corrected cluster level). These clusters showed stronger
increases across load in patients than in controls. On the
other hand, there were no significant clusters showing
stronger increases across load in controls than in patients at
the corrected or uncorrected cluster level, and there were no
significant voxels at the chosen height threshold (p < 0.001).
The prefrontal clusters that emerged in this interaction
analysis appeared not to be part of the activation seen in
response to load across both groups (Fig. 1) but appeared to
be neighbouring it. In order to verify this, the group-by-
load interaction contrast was masked with the contrast
image resulting from the main effect of load; the two
prefrontal areas from the interaction analysis also emerged
in this masked analysis, indicating that these are voxels that
show an additional increase with load in the patient group
but not in the controls and not in the combined group.
To better understand the origin of these group-by-load
interaction effects, the mean BOLD signal in each of the
two frontal clusters that showed a significant interaction
effect was extracted as described above and repeated
measures ANOVAs with the within-subjects factor of load
were run in SPSS separately for the two groups. In the left
prefrontal cluster, we found a linear increase in BOLD as a
Table 2 N-back task performance data by group
Patients (N=45) Controls (N=19)
0-back correct responses 84.89 (19.15) 87.51 (13.91)
1-back correct responses 62.10 (28.92) 74.89 (22.42)
2-back correct responses 43.18 (26.54) 51.58 (23.19)
0-back omissions 8.03 (9.62) 8.56 (9.26)
1-back omissions 15.75 (16.23) 14.81 (10.96)
2-back omissions 27.49 (20.92) 29.72 (18.15)
0-back latency 233.95 (130.96) 191.36 (145.83)
1-back latency 296.41 (210.07) 293.70 (145.88)
2-back latency 490.24 (353.46) 390.63 (213.42)
Data represent means. Standard deviations are given in parentheses.
Correct responses and omissions are given in percent; latency is given
in milliseconds.
Fig. 1 Main effect of load on BOLD across groups. The figure depicts significant BOLD response as a function of load on the n-back working
memory task across both groups (p < 0.05, FWE corrected voxel level)
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function of load in the patient group (F[2,88] = 6.65, p =
0.002, ηp
2 = 0.13) but not in the controls (F[2,36] = 0.35,
p = 0.71, ηp
2 = 0.02). Similarly, in the right prefrontal
cluster, there was a linear increase in BOLD as a function
of load in the patient group (F[2,88] = 8.26, p = 0.001,
ηp
2 = 0.16) but not in the controls (F[2,36] = 0.77, p =
0.47, ηp
2 = 0.04).
Taken together, this pattern indicates that patients
showed a significantly greater BOLD increase in response
to working memory load than controls in lateral prefrontal
cortical areas that did not show a significant main effect of
load.
Association of BOLD with performance level in the patient
group
In keeping with the analysis plan, the patient group was
split into those with high and low performance along the
patient group's median (62.49%), yielding two groups of N =
22 each (the subject with the median score was
excluded). N-back data of the two groups are summarised
in Table 3. Importantly, the high- and low-performing
patient groups did not differ from each other in any
demographic or clinical variables (all p > 0.05). However,
the two patient groups differed significantly from each
other in percent correct response at each level of load (all
F > 11.88, p < 0.002), as expected. They also differed
with regards to omission errors (all F > 6.82, p < 0.02)
but not in reaction time (all F < 1.85, p > 0.18).
At the level of BOLD, each patient subgroup showed
similar activation increases in response to load as the
combined group (see Online Resource 1). An anatomically
unconstrained voxelwise comparison between the two
patient groups did not find a main effect of performance
and there was no performance-by-load interaction (at p =
0.05, corrected cluster level). A comparison of the
Fig. 2 Group-by-load interactions in BOLD response. The upper part
of the figure depicts in red the areas that show a significant main
effect of load and in blue the two prefrontal areas that show a
significant group-by-load interaction. The selection of the two coronal
slices corresponds to the Talairach y coordinates of the peak voxel for
the right (y =18) and left (y =17) PFC clusters, respectively. The
lower parts of the figure depict the nature of the interaction effects
separately for left and right PFC
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prefrontal clusters that had showed group-by-load interactions
above similarly did not yield significant main effects of
performance for either cluster (both p > 0.79). However,
there was a significant performance-by-load interaction for
the left (F[2,84] = 4.09, p = 0.02, ηp
2 = 0.09) but not right
(p = 0.24, ηp
2 = 0.03) cluster. In order to better understand
this interaction, within-subject ANOVAs of load in the left
prefrontal cluster were calculated separately for the two
performance groups. These showed that the high- (F[2,42] =
9.63, p < 0.001, ηp
2 = 0.31) but not the low-performing
patients (p = 0.83, ηp
2 = 0.009) showed a statistically
significant linear increase in BOLD with load (Fig. 3).
Effects of antipsychotic treatment
The split according to treatment yielded two groups of
patients, those treated with FGA (N = 6) and those treated
with SGA (N = 38) antipsychotics (N = 1 excluded). N-
back performance data of the treatment groups are
summarised in Table 3. There were no significant associ-
ations of treatment with any demographic variables, clinical
variables, or anticholinergic, antidepressant, mood stabil-
iser, or benzodiazepine treatment (all p > 0.34), and the
treatment factor did not significantly interact with the
performance variable (χ2 = 0.89, df = 1, p = 0.35): in
the SGA group, there were 17 low- and 20 high-performing
patients, and in the FGA group, there were four low- and
two high-performing patients. There were no main effects
of treatment (all p > 0.18) or treatment-by-load interactions
(all p > 0.22) on n-back task performance; therefore, any
treatment effects on BOLD reported below are considered
to be independent of performance effects.
At the level of BOLD, an unrestricted voxelwise analysis
did not yield any significant differences between the two
treatment groups or treatment-by-load interactions (all p >
0.05, corrected cluster level). When considering the
extracted prefrontal ROIs, no main effects of treatment
were seen in either cluster (both p > 0.51). However, there
was a significant treatment-by-load interaction (F[2,84] =
5.16, p = 0.008, ηp
2 = 0.11) in the left prefrontal cluster.
This interaction (Fig. 4) indicated that patients treated with
SGA showed an increase in BOLD as a function of load,
whereas the patients treated with FGA showed a reduction.
The interaction effect appeared similar in the right
prefrontal cluster but did not reach statistical significance
(p = 0.13). A further split of the SGA into those patients
treated with clozapine (N = 10), risperidone (N = 7), and
olanzapine (N = 16) did not yield any significant group or
interaction effects for the prefrontal ROIs. Therefore, the
SGA group as a whole showed a stronger parametric left
prefrontal BOLD increase than the FGA group, with no


















Fig. 3 Performance-by-load interaction in BOLD response. The figure
shows the performance-by-load interaction for the left PFC. The patient
sample is split along the median correct response rate into those with high
performance (N = 22) and those with low performance (N = 22). The x
axis shows the three conditions of the n-back working memory task
Table 3 Performance data by patient subgroups
Performance subgroups Treatment subgroups
High (N=22) Low (N=22) First-generation (N=6) Second-generation (N=38)
0-back correct responses 93.52 (5.77) 75.64 (23.63) 89.11 (9.22) 84.07 (20.50)
1-back correct responses 85.07 (10.73) 39.87 (23.55) 60.48 (31.03) 63.27 (28.81)
2-back correct responses 62.17 (23.96) 24.20 (12.11) 43.59 (30.75) 43.77 (26.32)
0-back omissions 4.61 (4.15) 11.76 (12.16) 8.00 (6.14) 8.07 (10.24)
1-back omissions 7.34 (6.11) 24.74 (18.65) 24.05 (21.22) 14.21 (15.39)
2-back omissions 18.88 (17.24) 36.92 (20.80) 37.95 (24.36) 25.26 (20.11)
0-back latency 220.16 (103.08) 254.48 (153.69) 268.35 (129.35) 218.62 (117.80)
1-back latency 252.88 (144.17) 303.00 (195.38) 442.97 (228.72) 264.07 (193.76)
2-back latency 403.39 (267.89) 537.96 (380.03) 460.99 (237.67) 488.19 (372.91)
Data represent means. Standard deviations are given in parentheses. Correct responses and omissions are given in percent; latency is given in
msec. The performance and treatment groups were not significantly associated (see “Results”).
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Association of BOLD with symptom severity
There were no significant correlations of BOLD from the
combined n-back activations with PANSS total or subscale
scores (all p > 0.05, corrected cluster level). Similarly, there
were no correlations between the extracted ROIs and
PANSS symptom scores (all p > 0.06).
Discussion
This study used fMRI to investigate the BOLD response
during a parametric spatial working memory task in stable
outpatients with schizophrenia and healthy control partici-
pants. It was found that (1) patients and controls did not differ
significantly in task performance, (2) both groups showed
deterioration in performance and increase in BOLD signal in
response to increasing working memory load, (3) the patient
group as a whole showed stronger BOLD signal in occipital
and prefrontal cortical areas additional to prefrontal areas
activated in both groups, (3) this difference increased with
increasing working memory load in prefrontal areas, (4)
patients with good performance showed greater left prefrontal
BOLD increase in response to increasing working memory
load than patients with poor performance, and (5) second-
generation antipsychotics (SGA) were associated with a
greater parametric increase in left prefrontal BOLD in response
to increasing working memory load than first-generation
antipsychotics (FGA), independent of the performance effects.
Patient-control differences
Working memory deficits in schizophrenia have often been
demonstrated and it is important to understand this
impairment in relation to the pathophysiology, genetics,
and treatment of schizophrenia (Barch and Smith 2008;
Goldman-Rakic 1994). However, there is still considerable
lack of clarity concerning the neural mechanisms that
mediate these cognitive impairments. Given the importance
of the neurophysiological level of analysis in genetic
(Meyer-Lindenberg and Weinberger 2006) and pharmaco-
logical (Migo et al. 2011) studies of schizophrenia, the aim
of this study was to further address this issue.
Patients and controls did not differ in working memory
performance in this study (see also Tan et al. 2005). At the
level of BOLD, it was found that patients with schizophre-
nia displayed significantly stronger activation than controls
in lateral prefrontal cortex and left occipital cortex (extend-
ing into the cerebellum) during task performance. Addi-
tionally, the group difference in prefrontal cortex became
stronger with increasing load. The prefrontal cortex clusters
were located to superior and middle frontal gyrus as well as
medial prefrontal cortex. These prefrontal hyperactivations
in patients appeared to be recruited in addition to prefrontal
areas that were activated in the main effect of working
memory load in both groups.
Previous brain activation studies of schizophrenia
patients have variably shown increased, decreased, or
comparable frontal activation levels in patients. These
discrepancies have been attributed to a number of variables
including performance and task difficulty (Callicott et al.
2003; Manoach 2003; Potkin et al. 2009). As outlined in
detail elsewhere (Linden 2009), the pattern of schizophrenia-
control differences in BOLD signal and task performance
can take on different forms, indicating qualitatively different,
reduced, compensatory, aberrant, or inefficient neural re-
sponse. The results of the current study indicate that areas
activated by both groups are activated to a similar extent;
however, patients additionally activated lateral prefrontal
areas, an effect that became more pronounced with increas-
ing task demands. Bearing in mind that the patients have
psychotic symptoms and general clinical impairments, this
pattern suggests the operation of compensatory neural
mechanisms that led to overall successful task performance
when compared to healthy controls. A number of previous
studies have similarly observed compensatory BOLD
increases on the background of comparable task performance
in schizophrenia patients (Karch et al. 2009; Lee et al. 2008;
Potkin et al. 2009; Royer et al. 2009; Tan et al. 2005; van
Raalten et al. 2008; see also meta-analysis by Minzenberg et
al. 2009). However, while the patients' recruitment of
additional areas in our study may represent a behaviourally
successful compensatory mechanism, it is also neurally
inefficient as it requires additional resources in order to
achieve a comparable performance levels as the controls. Of
interest, it should be noted that compensatory hyperactiva-


















Fig. 4 Treatment-by-load interaction in BOLD response. The figure
shows the treatment-by-load interaction for the left PFC. The patient
sample is split into those treated with first-generation antipsychotics (N =
6) and those treated with second-generation antipsychotics (N = 38). The
x axis shows the three conditions of the n-back working memory task
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in other psychiatric conditions such as obsessive–compulsive
disorder (Henseler et al. 2008).
Performance effects in patients
The left prefrontal BOLD increases in response to working
memory load were more pronounced in patients with high
levels of performance than in patients with low perfor-
mance levels. The finding of performance-related activation
levels in the patients is in part compatible with existing
models which attribute group differences in BOLD to
variation in task performance (Callicott et al. 2003;
Manoach 2003). These models suggested that relatively
unimpaired performance may be associated with increased
BOLD signal, whereas lower performance may be associ-
ated with reductions in BOLD, e.g., hypofrontality. Given
that high-performing patients in this study showed a
stronger increase in activation with increasing task demands
than low-performing patients it may be speculated that this
may perhaps be compatible with low-performing patients
not being able to further increase their BOLD beyond a
certain level of task difficulty, which could have resulted in
(or stemmed from) their lower working memory capacity.
Relating this pattern to the inverted U curves depicted by
Manoach (2003) and Callicott et al. (2003), it may be
surmised that low-performing patients are already at the top
or on the downward slope of the inverted U.
Treatment effects in patients
The cross-sectional treatment effects observed here are
compatible with some previous evidence (see “Introduction”).
Patients treated with SGA showed load-related increases in
left prefrontal BOLD, whereas those on FGA did not; it is
important to note that this effect represents an interaction
effect of working memory load and treatment but not a
treatment main effect. Importantly, the FGA and SGA patient
groups did not differ in demographic, clinical, or perfor-
mance variables. An analysis of individual SGA compounds
(clozapine, risperidone, olanzapine) did not yield any differ-
ences amongst these. As stated earlier, a number of
pharmacological fMRI studies of antipsychotic compounds
in schizophrenia have shown stronger BOLD signal with
SGA compared to FGA. The strongest evidence for this effect
comes from longitudinal studies which have shown that SGA
improve cortical activations, thus normalising previous hypo-
activations (review, Davis et al. 2005; Kumari and Cooke
2006; Migo et al. 2011). The present study observed this
effect in a cross-sectional design. The effect was seen despite
the small number of patients treated with FGA, a factor that
can be attributed to current guidelines in clinical practice.
However, it should be noted that not all previous studies
have found this effect. For example, Surguladze et al.
(2007) observed that patients on FGA showed an increase
in ventromedial prefrontal BOLD as a function of working
memory load, whereas patients treated with risperidone and
healthy controls did not. Conversely, a lateral ventral
prefrontal area studied by Surguladze et al. (2007) showed
an increase with load only in controls but not in FGA- or
risperidone-treated patients. An important difference between
their study and ours is that in Surguladze et al. (2007), patients
treated with FGA displayed significantly impaired task
performance relative to risperidone-treated patients, whereas
in our study, there were no significant drug effects on the
level of task performance. Furthermore, there is evidence for
relative functional specificity within prefrontal cortices. For
example, studies have shown bilaterally increased DPFC
(BA9/46) activity during rule discovery but increased VPFC
(BA47/12) activity with changes in card-sorting rule on the
WCST (Monchi et al. 2001). It is possible that SGAs have
different effects on dorsal and ventral prefrontal brain
regions.
The observation that in this study, working memory task
performance did not differ between the two treatment
groups, is noteworthy given that there were differences
between the two groups at the level of BOLD in response to
working memory load increase. Dissociations of effects at
behavioural and neural levels of analysis in fMRI designs
have previously been described in relation to experimental
cognitive neuroscience (Wilkinson and Halligan 2004), but
similar arguments may apply to pharmacological fMRI
studies (Migo et al. 2011). Specifically, in this instance, it
may be argued that our data provide evidence for the notion
that the BOLD signal may be a more sensitive measure of
pharmacological treatment effects than behavioural meas-
ures (Honey and Bullmore 2004) analogous to findings in
the neurochemical imaging literature (Fannon et al. 2003).
A likely pharmacological explanation of the treatment
effects in this study may be the richer pharmacological
profile of SGA compounds which rely not just on D2
receptor antagonism but also act on other neurotransmitter
systems such as the serotonergic system. However, the
group of SGA compounds used in this study is heteroge-
neous, thus not allowing a definitive explanation of the
neurotransmitter mechanisms underlying the effects ob-
served here.
Limitations
This study has a number of limitations. First, the patient
group treated with FGA was small (N = 6). This limitation
of the study stems from the fact that we used a naturalistic
design in a clinical environment where the majority of
schizophrenia patients are treated with SGA. The small size
of the FGA group could also be an explanation for the lack
of differences between the two patient groups in demo-
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graphic, clinical, or performance measures. An additional
limitation is that the group of SGA is pharmacologically
heterogeneous. Therefore, it cannot be concluded that there
is a single mechanism common to all these compounds by
which they affected BOLD in this study. It should also be
noted that the performance-by-load and treatment-by-load
interactions were observed only when considering individ-
ual ROIs but not at the voxelwise level. Previous studies
have noted that antipsychotic effects at the level of BOLD
may be of small to moderate effect size (Meisenzahl et al.
2006); therefore, replication using larger samples will be
important. A further limitation is the fact that some patients
were co-medicated with other compounds; these may
influence cognition and brain function. Finally, the effects
of pharmacological treatment should ideally be investigated
using more powerful longitudinal designs rather than cross-
sectional studies. Future longitudinal studies are needed to
further advance this field.
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